Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women.

Ratanasuwan W, Jariyasethpong T, Anekthananon T, Intalapaporn P, Kongpatanakul S, Pongnarin P, Wasinrapee P, Chantharojwong N, Raengsakulrach B, Peters PJ, McNicholl J, McConnell MS, Weidle PJ.

Open AIDS J. 2012;6:266-73. doi: 10.2174/1874613601206010266. Epub 2012 Dec 30.

2.

Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.

Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S, Limpongsanurak S, Jadwattanakul T, Eiamapichart P, Luesomboon W, Apisarnthanarak A, Kamudhamas A, Tangsathapornpong A, Vitavasiri C, Singhakowinta N, Attakornwattana V, Kriengsinyot R, Methajittiphun P, Chunloy K, Preetiyathorn W, Aumchantr T, Toro P, Abrams EJ, El-Sadr W, Phanuphak P.

HIV Med. 2007 Sep;8(6):357-66.

3.

Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.

Montaner JS, Cahn P, Zala C, Casssetti LI, Losso M, Hall DB, Wruck J, McDonough M, Gigliotti M, Robinson PA; 1100.1286 Study Team.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):41-6.

PMID:
12792354
4.

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB.

AIDS. 1999 Mar 11;13(4):479-86.

PMID:
10197376
5.

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.

Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, Shioda T, Khusmith S.

AIDS Res Ther. 2010 Mar 26;7:8. doi: 10.1186/1742-6405-7-8.

6.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.

AIDS. 2001 Jul 6;15(10):1261-8.

PMID:
11426070
7.

[Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].

Pitche P, Drobacheff-Thiebaut C, Gavignet B, Mercier M, Laurent R.

Ann Dermatol Venereol. 2005 Dec;132(12 Pt 1):970-4. French.

PMID:
16446639
8.
9.

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.

Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y.

Pharmacogenet Genomics. 2009 Feb;19(2):139-46. doi: 10.1097/FPC.0b013e32831d0faf.

PMID:
19104471
10.

HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients.

Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Tunthanathip P, Nakayama EE, Shioda T.

AIDS Res Ther. 2009 Oct 21;6:22. doi: 10.1186/1742-6405-6-22.

11.

Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.

Manosuthi W, Kiertiburanakul S, Chaovavanich A, Sungkanuparph S.

J Med Assoc Thai. 2007 Feb;90(2):244-50.

PMID:
17375627
12.
13.

Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.

Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, Mahasirimongkol S, Sura T, Chantratita W.

Curr HIV Res. 2008 Jan;6(1):65-9.

PMID:
18288977
14.

Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.

Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Takahashi A, Kubo M, Kamatani N, Chantratita W, Nakamura Y.

Clin Infect Dis. 2011 Aug;53(4):341-8. doi: 10.1093/cid/cir403.

PMID:
21810746
15.

Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.

Aaron E, Kempf MC, Criniti S, Tedaldi E, Gracely E, Warriner A, Kumar R, Bachmann LH.

PLoS One. 2010 Sep 7;5(9):e12617. doi: 10.1371/journal.pone.0012617.

16.

Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.

Cressey TR, Jourdain G, Lallemant MJ, Kunkeaw S, Jackson JB, Musoke P, Capparelli E, Mirochnick M.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):283-8.

PMID:
15735445
17.

[Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital].

Kondo W, Astori Ade A, Gomes Sel-K, Fernandes Rde B, Sasaki Md, Sbalqueiro RL.

Rev Bras Ginecol Obstet. 2008 Jan;30(1):19-24. Portuguese.

18.

Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.

Stringer JS, McConnell MS, Kiarie J, Bolu O, Anekthananon T, Jariyasethpong T, Potter D, Mutsotso W, Borkowf CB, Mbori-Ngacha D, Muiruri P, Ong'ech JO, Zulu I, Njobvu L, Jetsawang B, Pathak S, Bulterys M, Shaffer N, Weidle PJ.

PLoS Med. 2010 Feb 16;7(2):e1000233. doi: 10.1371/journal.pmed.1000233.

19.
20.

A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk.

Jackson JB, Barnett S, Piwowar-Manning E, Apuzzo L, Raines C, Hendrix C, Hamzeh F, Gallant J.

AIDS. 2003 Mar 7;17(4):547-53.

PMID:
12598775

Supplemental Content

Support Center